BGLC Relative Valuation
BGLC's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, BGLC is overvalued; if below, it's undervalued.
Historical Valuation
BioNexus Gene Lab Corp (BGLC) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of 0.00. The fair price of BioNexus Gene Lab Corp (BGLC) is between to according to relative valuation methord.
Relative Value
Fair Zone
-
Current Price：4.33
Fair
0.00
PE
1Y
3Y
5Y
Trailing
Forward
0.00
EV/EBITDA
BioNexus Gene Lab Corp. (BGLC) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBITDA of 0.00 falls within the Strongly Undervalued range.
0.00
EV/EBIT
BioNexus Gene Lab Corp. (BGLC) has a current EV/EBIT of 0.00. The 5-year average EV/EBIT is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBIT of 0.00 falls within the Strongly Undervalued range.
0.00
PS
BioNexus Gene Lab Corp. (BGLC) has a current PS of 0.00. The 5-year average PS is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward PS of 0.00 falls within the Strongly Undervalued range.
0.00
P/OCF
BioNexus Gene Lab Corp. (BGLC) has a current P/OCF of 0.00. The 5-year average P/OCF is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward P/OCF of 0.00 falls within the Strongly Undervalued range.
0.00
P/FCF
BioNexus Gene Lab Corp. (BGLC) has a current P/FCF of 0.00. The 5-year average P/FCF is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward P/FCF of 0.00 falls within the Strongly Undervalued range.
BioNexus Gene Lab Corp (BGLC) has a current Price-to-Book (P/B) ratio of 1.14. Compared to its 3-year average P/B ratio of 3.04 , the current P/B ratio is approximately -62.52% higher. Relative to its 5-year average P/B ratio of 14.18, the current P/B ratio is about -91.95% higher. BioNexus Gene Lab Corp (BGLC) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -23.73%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -17.32% , the current FCF yield is about -100.00% lower.
1.14
P/B
Median3y
3.04
Median5y
14.18
-34.93
FCF Yield
Median3y
-23.73
Median5y
-17.32
Competitors Valuation Multiple
The average P/S ratio for BGLC's competitors is 0.00, providing a benchmark for relative valuation. BioNexus Gene Lab Corp Corp (BGLC) exhibits a P/S ratio of 0.00, which is NaN% above the industry average. Given its robust revenue growth of -3.29%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of BGLC increased by 54.81% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -1.66 to -3.39.
The secondary factor is the Revenue Growth, contributed -3.29%to the performance.
Overall, the performance of BGLC in the past 1 year is driven by P/E Change. Which is more unsustainable.
People Also Watch
FAQ
Is BioNexus Gene Lab Corp (BGLC) currently overvalued or undervalued?
What is BioNexus Gene Lab Corp (BGLC) fair value?
How does BGLC's valuation metrics compare to the industry average?
What is the current P/B ratio for BioNexus Gene Lab Corp (BGLC) as of Dec 05 2025?
What is the current FCF Yield for BioNexus Gene Lab Corp (BGLC) as of Dec 05 2025?
What is the current Forward P/E ratio for BioNexus Gene Lab Corp (BGLC) as of Dec 05 2025?